source
- Biopharma must pair innovation with operational readiness to scale therapiesThe article argues that breakthrough science alone no longer guarantees success in biopharma. Companies now face pressure to turn discoveries into reliably manufactured, delivered, and scalable pro…
- Novo Nordisk aims to bring triple-G obesity injection to market by 2030Novo Nordisk said it plans to launch a triple‑G obesity injection by 2030. The drug would combine agonist activity at the GLP‑1, GIP and glucagon receptors, a class that researchers believe could b…